The parallel, double-blind, placebo-controlled, randomized pilot study investigated LPLDL in 16 hypercholesterolemic adults. Participants were given 4x109CFU LPLDL or a placebo once daily for six weeks, followed by a three-week washout period. Fasting blood samples were collected for blood lipid, liver function, and vitamin D analysis.
After 6 weeks of supplementation, statistically significant reductions were noted in total cholesterol by an average of 34.6%, with an average reduction of LDL cholesterol of 28.4%, as compared to the placebo. No changes were observed in liver function biomarkers or vitamin D.
Related: Weight Management Ingredient Receives Health Canada Approval Microbiome: The More You Know Pre- and Probiotics Studied for Sleep and Stress Support
Stephen O’Hara, CEO at OptiBiotix, commented in a press release: “The results of this study are remarkable and firmly establish LPLDLas the probiotic for heart health. Our previous human intervention studies have highlighted LPLDLas an excellent candidate to reduce cholesterol across different patient groups and countries. Now, with the statistically significant results of our latest study, both partners and consumers can rest assured they are using a science-backed probiotic that not only reduces total cholesterol, but multiple risk factors associated with CHD. For the industry, this is a significant step forward for a probiotic that can truly make a difference, demonstrating that LPLDLchampions scientific evidence to deliver impressive results.”
